The cell-intrinsic antiproliferative effects of HIF2 inhibitors in kidney cancer are caused by loss of cyclin D1 activity, and upregulation of cyclin D2 or D3 are potential resistance mechanisms. Here, CCND1 is linked to kidney cancer.